Business

Adamis Pharmaceuticals has announced that it will exclusively license and then acquire 3M’s Taper API-only dry powder inhaler. The company said that “Upon completion of development and clinical activities required to obtain required regulatory approval,… Read more . . .

Grupo Ferrer Internacional has launched Adasuve Staccato loxapine in Germany, triggering a $1.25 million milestone payment to Adasuve developer and manufacturer Alexza Pharmaceuticals, Alexza has announced. Adasuve was approved in the EU in February 2013… Read more . . .

Depomed has announced that it has paid $4 million for US and Canadian rights to Lazanda fentanyl nasal spray from Archimedes Pharma Limited. Lazanda was approved by the FDA for the treatment of breakthrough cancer… Read more . . .

Indian contract research and manufacturing company Kemwell Biopharma has acquired North Carolina-based CRO Cirrus Pharmaceuticals, which offers development services for inhaled and nasal drugs among other dosage forms. Cirrus also provides analytical services for OINDPs.… Read more . . .

Mylan has announced that the United States District Court for the Northern District of West Virginia granted a Mylan motion for partial summary judgment and found that Teva’s generic formoterol fumarate inhalation solution infringes US… Read more . . .

Insmed Incorporated has announced a proposed underwritten public offering of $60 million of its common stock to fund continued clinical development, regulatory efforts, and commercialization of Arikace inhaled liposomal amikacin, its lead product. The company… Read more . . .

The US District Court for the Southern District of New York has issued a final judgment and order affirming the validity of five patents related to Mylan’s Perforomist formoterol fumarate inhalation solution and stating that… Read more . . .

According to multi-industry laboratory company Intertek, it has acquired OINDP testing specialist Melbourn Scientific. In its announcement, Intertek cites Melbourn’s “profound expertise in all aspects of characterization of orally inhaled and intra-nasal products (OINDP)” and… Read more . . .

According to RDD Online, the RDD China meeting scheduled to take place October 16-18, 2013 in Beijing has been cancelled due to “contractual problems which made it impossible for RDD to guarantee the quality of… Read more . . .